Repligen's GAAP net income for 3 months of 2022 was $46.964 million, up 59.5% from $29.45 million in the previous year. Revenue increased 44.5% to $206.4 million from $142.837 million a year earlier.

Repligen's GAAP net income for 2021 was $128.291 million, up 2.14 times from $59.926 million in the previous year. Revenue increased 83.1% to $670.534 million from $366.26 million a year earlier.

Repligen's GAAP net income for 9M 2021 was $99.181 million, up 2.46 times from $40.228 million in the previous year. Revenue increased 87.9% to $484.013 million from $257.612 million a year earlier.

Repligen is acquiring Avitide, a manufacturer of affinity ligands for the biopharmaceutical industry. The company expects Avitide to generate $10 million in revenue in 2022. The deal is valued at $150 million. Half of that amount will be paid in cash and the other half in Repligen stock. The deal is scheduled to close in Q3 2021.